Effects of Switching from Anti-VEGF Treatment to Triamcinolone Acetonide in Eyes with Refractory Macular Edema Associated with Diabetic Retinopathy or Retinal Vein Occlusion

Table 1

Clinical data before switching to TA treatment.

	DME	RVO-ME	value
Age (years),			0.002^1
Men : women	7 : 4	5 : 4	0.53^2
BCVA (logMAR), D (Snellen equivalent)	(20/80)	(20/58)	0.28^1
CRT (μm),			0.08^1
IOP (mmHg),			0.56^1
STTA : IVTA	7 : 4	8 : 1	0.22^2
Phakic eye : pseudophakic eye	7 : 4	6 : 3	0.63^2
Type of macular edema	SRD: 3	SRD: 2	0.40^3
	CME: 1	CME: 3
	Sponge-like: 7	Sponge-like: 4
History of photocoagulation treatment	PRP: 10	PRP: 2	0.006^3
	Focal PC: 1	Focal PC: 3
	No PC: 0	No PC: 4
Number of anti-VEGF injections, (range)	(6-50)	(6-36)	0.07^1
Duration of treatment with anti-VEGF (weeks), (range)	(34-275)	(32-417)	0.07^1

DME = diabetic macular edema; RVO-ME = macular edema associated with retinal vein occlusion; SD = standard deviation; BCVA = best-corrected visual acuity; CRT = central retinal thickness; IOP = intraocular pressure; STTA = sub-Tenon triamcinolone acetonide injection; IVTA = intravitreal triamcinolone acetonide injection; SRD = serous retinal detachment; CME = cystoid macular edema; PRP = panretinal photocoagulation; PC = photocoagulation; VEGF = vascular endothelial growth factor.